Savara Inc (SVRA) stock is experiencing a significant pre-market surge of 6.32% following a series of positive analyst actions. The biotechnology company has received multiple upgrades and price target increases, boosting investor confidence ahead of the market open.
H.C. Wainwright has made a notable upgrade, raising their rating on Savara from Neutral to Buy. Analyst Andrew Fein has also significantly increased the price target from $2 to $5, citing improved resubmission prospects for the company. Simultaneously, Oppenheimer has raised its price target on Savara from $5 to $6, while maintaining an Outperform rating.
These bullish moves from analysts reflect growing optimism about Savara's potential. According to FactSet, the company now has an average rating of Buy and a mean price target of $7.93. The pre-market rally suggests that investors are responding positively to these upward revisions, potentially anticipating stronger performance from Savara in the near future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.